Glenmark Pharmaceuticals is currently trading at Rs. 346.55, up by 1.15 points or 0.33% from its previous closing of Rs. 345.40 on the BSE.
The scrip opened at Rs. 347.00 and has touched a high and low of Rs. 350.65 and Rs. 345.60 respectively. So far 17675 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 706.90 on 31-Dec-2018 and a 52 week low of Rs. 343.45 on 25-Sep-2019.
Last one week high and low of the scrip stood at Rs. 360.20 and Rs. 343.45 respectively. The current market cap of the company is Rs. 9794.06 crore.
The promoters holding in the company stood at 46.58%, while Institutions and Non-Institutions held 38.72% and 14.71% respectively.
Glenmark Pharmaceuticals has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the second consecutive year in a row. DJSI is one of the world’s most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index.
The DJSI analyses companies on the corporate economic, environmental and social performance, in order to assess issues such as but not limited to corporate governance, risk management, branding, climate change mitigation, supply chain standards and labor practices amongst others. The inclusion in this list is considered highly prestigious by global investors, financial analysts and other stakeholders and also serves as a benchmark for investors who integrate sustainability considerations into their portfolios.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
